[{"address1": "41 \u2013 47 Colin Street", "address2": "Suite 3", "city": "West Perth", "state": "WA", "zip": "6005", "country": "Australia", "phone": "61 8 6555 2945", "fax": "61 8 6210 1153", "website": "https://www.botanixpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Vincent P. Ippolito", "age": 65, "title": "MD & Executive Chairman", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 424060, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Howie  McKibbon", "title": "Chief Executive Officer", "fiscalYear": 2024, "totalPay": 639294, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Graeme  Morissey", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 63568, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Callahan L.L.B., M.B.A., MBA LLB", "age": 51, "title": "Executive Director", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 247190, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack  Hoblitzell Ph.D.", "title": "Senior Vice President of Pharmaceutical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patricia S. Walker M.D., Ph.D.", "age": 65, "title": "Chief Medical Adviser", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Boris  Meyerson Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Morgan", "title": "Head of Corporate Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Wojciechowski", "title": "Head of HCP Marketing & Sales Training", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin", "age": 49, "title": "Company Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0, "open": 0.295, "dayLow": 0.295, "dayHigh": 0.295, "regularMarketPreviousClose": 0.0, "regularMarketOpen": 0.295, "regularMarketDayLow": 0.295, "regularMarketDayHigh": 0.295, "payoutRatio": 0.0, "volume": 10000, "regularMarketVolume": 10000, "averageVolume": 7816, "averageVolume10days": 12429, "averageDailyVolume10Day": 12429, "bid": 0.18, "ask": 0.27, "bidSize": 0, "askSize": 0, "marketCap": 500536832, "fiftyTwoWeekLow": 0.0085, "fiftyTwoWeekHigh": 0.5, "fiftyDayAverage": 0.283908, "twoHundredDayAverage": 0.237388, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "profitMargins": 0.0, "sharesOutstanding": 1829619968, "heldPercentInsiders": 0.13003999, "heldPercentInstitutions": 0.13424, "impliedSharesOutstanding": 1853840000, "bookValue": 0.06, "priceToBook": 4.5000005, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "trailingEps": -0.01, "52WeekChange": 1.0769231, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 0.27, "recommendationKey": "none", "revenuePerShare": 0.001, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "AUD", "symbol": "BXPHF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Botanix Pharmaceuticals Ltd.", "longName": "Botanix Pharmaceuticals Limited", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.27, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1568035800000, "regularMarketChange": 0.0, "regularMarketDayRange": "0.295 - 0.295", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 7816, "fiftyTwoWeekLowChange": 0.2615, "fiftyTwoWeekLowChangePercent": 30.764704, "fiftyTwoWeekRange": "0.0085 - 0.5", "fiftyTwoWeekHighChange": -0.22999999, "fiftyTwoWeekHighChangePercent": -0.45999998, "fiftyTwoWeekChangePercent": 107.692314, "earningsTimestamp": 1740517993, "earningsTimestampStart": 1740517993, "earningsTimestampEnd": 1740517993, "earningsCallTimestampStart": 1726533000, "earningsCallTimestampEnd": 1726533000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.01, "fiftyDayAverageChange": -0.013907999, "fiftyDayAverageChangePercent": -0.048987694, "twoHundredDayAverageChange": 0.03261201, "twoHundredDayAverageChangePercent": 0.13737851, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "marketState": "CLOSED", "corporateActions": [], "gmtOffSetMilliseconds": -18000000, "regularMarketTime": 1740772800, "exchange": "PNK", "messageBoardId": "finmb_324672225", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "market": "us_market", "esgPopulated": false, "displayName": "Botanix Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]